Pharmacogenetics of anticoagulants

Human Genomics and Proteomics

Volumn , Issue , 2010, Pages

  Rane, Anders ^a,b   Lindh, Jonatan D ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ANTICOAGULANT AGENT; PHENPROCOUMON; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; DRUG HALF LIFE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HIGH RISK POPULATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 77957861093     PISSN: None     EISSN: 17574242     Source Type: Journal    
DOI: 10.4061/2010/754919     Document Type: Review

References (52)

1. Routledge P. A., Chapman P. H., Davies D. M., Rawlins M. D., Factors affecting warfarin requirements. A prospective population study European Journal of Clinical Pharmacology 1979 15 5 319 322
2. Gage B. F., Eby C., Milligan P. E., Banet G. A., Duncan J. R., McLeod H. L., Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin Thrombosis and Haemostasis 2004 91 1 87 94
3. Klein T. E., Estimation of the warfarin dose with clinical and pharmacogenetic data New England Journal of Medicine 2009 360 8 753 764
4. Wadelius M., Chen L. Y., Lindh J. D., Eriksson N., Ghori M. J. R., Bumpstead S., Holm L., McGinnis R., Rane A., Deloukas P., The largest prospective warfarin-treated cohort supports genetic forecasting Blood 2009 113 4 784 792
5. Lindh J. D., Holm L., Dahl M.-L., Alfredsson L., Rane A., Incidence and predictors of severe bleeding during warfarin treatment Journal of Thrombosis and Thrombolysis 2008 25 2 151 159
6. WHO, Glossary of terms related to patient and medication safety. Vol 2008: Council of Euorope: Committee ofExperts on Management of Safety and Quality in Health Care (SP-SQS) Expert Group on Safe Medication Practices 2005
7. Landefeld C. S., Goldman L., Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy American Journal of Medicine 1989 87 2 144 152
8. Fihn S. D., Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group Annals of Internal Medicine 1993 118 7 511 520
9. McMahan D. A., Smith D. M., Carey M. A., Zhou X. H., Risk of major hemorrhage for outpatients treated with warfarin Journal of General Internal Medicine 1998 13 5 311 316
10. Petitti D. B., Strom B. L., Melmon K. L., Prothrombin time ratio and other factors associated with bleeding in patients treated with warfarin Journal of Clinical Epidemiology 1989 42 8 759 764
11. White R. H., Beyth R. J., Zhou H., Romano P. S., Major bleeding after hospitalization for deep-venous thrombosis American Journal of Medicine 1999 107 5 414 424
12. Rettie A. E., Korzekwa K. R., Kunze K. L., Lawrence R. F., Craig Eddy A., Aoyama T., Gelboin H. V., Gonzalez F. J., Trager W. F., Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarindrug interactions Chemical Research in Toxicology 1992 5 1 54 59
13. Kaminsky L. S., Zhang Z.-Y., Human P450 metabolism of warfarin Pharmacology and Therapeutics 1997 73 1 67 74
14. Aithal G. P., Day C. P., Kesteven P. J. L., Daly A. K., Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications Lancet 1999 353 9154 717 719
15. Kamali F., Khan T. I., King B. P., Frearson R., Kesteven P., Wood P., Daly A. K., Wynne H., Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin Clinical Pharmacology and Therapeutics 2004 75 3 204 212
16. Shikata E., Ieiri I., Ishiguro S., Aono H., Inoue K., Koide T., Ohgi S., Otsubo K., Association of pharmacokinetic (CY72C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and -glutamyl carboxylase) gene variants with warfarin sensitivity Blood 2004 103 7 2630 2635
17. Higashi M. K., Veenstra D. L., Midori Kondo L., Wittkowsky A. K., Srinouanprachanh S. L., Farin F. M., Rettie A. E., Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy Journal of the American Medical Association 2002 287 13 1690 1698
18. Loebstein R., Yonath H., Peleg D., Almog S., Rotenberg M., Lubetsky A., Roitelman J., Harats D., Halkin H., Ezra D., Interindividual variability in sensitivity to warfarin Clinical Pharmacology and Therapeutics 2001 70 2 159 164
19. Rettie A. E., Wienkers L. C., Gonzalez F. J., Trager W. F., Korzekwa K. R., Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9 Pharmacogenetics 1994 4 1 39 42
20. Crespi C. L., Miller V. P., The R144C change in the CYP2C92 allele alters interaction of the ctochrome P450 with NADPH:cytochrome P450 oxidoreductase Pharmacogenetics 1997 7 3 203 210
21. Li T., Chang C.-Y., Jin D.-Y., Lin P.-J., Khvorova A., Stafford D. W., Identification of the gene for vitamin K epoxide reductase Nature 2004 427 6974 541 544
22. Rost S., Fregin A., Ivaskevicius V., Conzelmann E., Hrtnagel K., Pelz H.-J., Lappegard K., Seifried E., Scharrer I., Tuddenham E. G. D., Mller C. R., Strom T. M., Oldenburg J., Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2 Nature 2004 427 6974 537 541
23. Wadelius M., Chen L. Y., Downes K., Ghori J., Hunt S., Eriksson N., Wallerman O., Melhus H., Wadelius C., Bentley D., Deloukas P., Common VKORC1 and GGCX polymorphisms associated with warfarin dose Pharmacogenomics Journal 2005 5 4 262 270
24. Sconce E. A., Khan T. I., Wynne H. A., Avery P., Monkhouse L., King B. P., Wood P., Kesteven P., Daly A. K., Kamali F., The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen Blood 2005 106 7 2329 2333
25. Rieder M. J., Reiner A. P., Gage B. F., Nickerson D. A., Eby C. S., McLeod H. L., Blough D. K., Thummel K. E., Veenstra D. L., Rettie A. E., Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose New England Journal of Medicine 2005 352 22 2285 2293
26. Yuan H.-Y., Chen J.-J., Lee M. T. M., Wung J.-C., Chen Y.-F., Charng M.-J., Lu M.-J., Hung C.-R., Wei C.-Y., Chen C.-H., Wu J.-Y., Chen Y.-T., A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity Human Molecular Genetics 2005 14 13 1745 1751
27. Yang L., Ge W., Yu F., Zhu H., Impact of VKORC1 gene polymorphism on interindividual and interethnic warfarin dosage requirementa systematic review and meta analysis Thrombosis Research 2010 125 4 e159 e166
28. D'Andrea G., D'Ambrosio R. L., Di Perna P., Chetta M., Santacroce R., Brancaccio V., Grandone E., Margaglione M., A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin Blood 2005 105 2 645 649
29. Herman D., Peternel P., Stegnar M., Breskvar K., Dolzan V., The influence of sequence variations in factor VII, -glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement Thrombosis and Haemostasis 2006 95 5 782 787
30. Wadelius M., Chen L. Y., Eriksson N., Bumpstead S., Ghori J., Wadelius C., Bentley D., McGinnis R., Deloukas P., Association of warfarin dose with genes involved in its action and metabolism Human Genetics 2007 121 1 23 34
31. Takeuchi F., McGinnis R., Bourgeois S., Barnes C., Eriksson N., Soranzo N., Whittaker P., Ranganath V., Kumanduri V., McLaren W., Holm L., Lindh J., Rane A., Wadelius M., Deloukas P., A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose PLoS Genetics 2009 5 3, article no. e1000433
32. McDonald M. G., Rieder M. J., Nakano M., Hsia C. K., Rettie A. E., CYP4F2 is a vitamin K1 oxidase: an explanation for altered warfarin dose in carriers of the V433M variant Molecular Pharmacology 2009 75 6 1337 1346
33. Millican E. A., Lenzini P. A., Milligan P. E., Grosso L., Eby C., Deych E., Grice G., Clohisy J. C., Barrack R. L., Burnett R. S. J., Voora D., Gatchel S., Tiemeier A., Gage B. F., Genetic-based dosing in orthopedic patients beginning warfarin therapy Blood 2007 110 5 1511 1515
34. Lenzini P. A., Grice G. R., Milligan P. E., Dowd M. B., Subherwal S., Deych E., Eby C. S., King C. R., Porche-sorbet R. M., Murphy C. V., Marchand R., Millican E. A., Barrack R. L., Clohisy J. C., Kronquist K., Gatchel S. K., Gage B. F., Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients Journal of Thrombosis and Haemostasis 2008 6 10 1655 1662
35. Horne B. D., Warfarin dosing algorithm refinements after 79 days of therapy based on pharmacogenetic, pharmacokinetic, clinical, and laboratory data Journal of the American College of Cardiology 2010 55
36. Li C., Schwarz U. I., Ritchie M. D., Roden D. M., Michael Stein C., Kurnik D., Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy Blood 2009 113 17 3925 3930
37. Michaud V., Vanier M.-C., Brouillette D., Roy D., Verret L., Noel N., Taillon I., O'Hara G., Gossard D., Champagne M., Goodman K., Renaud Y., Brown A., Phillips M., Ajami A. A., Turgeon J., Combination of phenotype assessments and CYP2C9-VKORC1 polymorphisms in the determination of warfarin dose requirements in heavily medicated patients Clinical Pharmacology and Therapeutics 2008 83 5 740 748
38. Lenzini P., Wadelius M., Kimmel S., Anderson J. L., Jorgensen A. L., Pirmohamed M., Caldwell M. D., Limdi N., Burmester J. K., Dowd M. B., Ngchaisuksiri P., Bss A. R., Chen J., Eriksson N., Rane A., Lindh J. D., Carlquist J. F., Horne B. D., Grice G., Milligan P. E., Eby C., Shin J., Kim H., Kurnik D., Stein C. M., McMillin G., Pendleton R. C., Berg R. L., Deloukas P., Gage B. F., Integration of genetic, clinical, and INR data to refine warfarin dosing Clinical Pharmacology and Therapeutics 2010 87 5 572 578
39. Ferder N. S., Eby C. S., Deych E., HARRIS J. K., Ridker P. M., Milligan P. E., Goldhaber S. Z., King C. R., Giri T., Mcleod H. L., Glynn R. J., Gage B. F., Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy Journal of Thrombosis and Haemostasis 2010 8 1 95 100
40. Ufer M., Comparative pharmacokinetics of vitamin K antagonists warfarin, phenprocoumon and acenocoumarol Clinical Pharmacokinetics 2005 44 12 1227 1246
41. Ufer M., Svensson J. O., Krausz K. W., Gelboin H. V., Rane A., Tybring G., Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro European Journal of Clinical Pharmacology 2004 60 3 173 182
42. Ufer M., Kammerer B., Kahlich R., Kirchheiner J., Yasar., Brockmller J., Rane A., Genetic polymorphisms of cytochrome P450 2C9 causing reduced phenprocoumon (S)-7-hydroxylation in vitro and in vivo Xenobiotica 2004 34 9 847 859
43. Kirchheiner J., Ufer M., Walter E.-C., Kammerer B., Kahlich R., Meisel C., Schwab M., Gleiter C. H., Rane A., Roots I., Brockmller J., Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- And S-phenprocoumon in healthy volunteers Pharmacogenetics 2004 14 1 19 26 (Pubitemid 38183958)
44. Cadamuro J., Dieplinger B., Felder T., Kedenko I., Mueller T., Haltmayer M., Patsch W., Oberkofler H., Genetic determinants of acenocoumarol and phenprocoumon maintenance dose requirements European Journal of Clinical Pharmacology 2010 66 3 253 260
45. Hummers-Pradier E., Hess S., Adham I. M., Papke T., Pieske B., Kochen M. M., Determination of bleeding risk using genetic markers in patients taking phenprocoumon European Journal of Clinical Pharmacology 2003 59 3 213 219
46. Visser L. E., van Schaik R. H. N., van Vliet M., Trienekens P. H., De Smet P. A. G. M., Vulto A. G., Hofman A., van Duijn C. M., Stricker B. H. CH., The risk of bleeding complications in patients with cytochrome P450 CYP2C92 or CYP2C93 alleles on acenocoumarol or phenprocoumon Thrombosis and Haemostasis 2004 92 1 61 66 (Pubitemid 39010868)
47. Tassies D., Freire C., Pijoan J., Maragall S., Monteagudo J., Ordinas A., Reverter J. C., Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation Haematologica 2002 87 11 1185 1191
48. Schalekamp T., Oosterhof M., Van Meegen E., Van Der Meer F. J. M., Conemans J., Hermans M., Meijerman I., De Boer A., Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status Clinical Pharmacology and Therapeutics 2004 76 5 409 417
49. Kovac M. K., Maslac A. R., Rakicevic L. B., The c.-1639GA polymorphism of the VKORC1 gene in Serbian population: retrospective study of the variability in response to oral anticoagulant therapy Blood Coagulation and Fibrinolysis 2010 21 6 558 563
50. Reitsma P. H., Van Der Heijden J. F., Groot A. P., Rosendaal F. R., Bller H. R., A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk PLoS Medicine 2005 2 10, article no. e312
51. Clarification of Optimal Anticoagulation Through Genetics (COAG), ClinicalTrials.gov Identifier NCT00839657. 2010, http://clinicaltrials.gov/ct2/ show/NCT00839657
52. Van Schie R. M. F., Wadelius M., Kamali F., Daly A. K., Manolopoulos V. G., De Boer A., Barallon R., Verhoef T. I., Kirchheiner J., Haschke-Becher E., Briz M., Rosendaal F. R., Redekop W. K., Pirmohamed M., Maitland-Van Der Zee A.-H., Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design Pharmacogenomics 2009 10 10 1687 1695